Table 3.

Inclusion criteria and response assessment for patients with melanoma brain metastases (MBMs)—completed studies

Author	Year	Therapy	Phase	Size	Symptoms	Prior therapy	Response assessment
Falchook	2012	Dabrafenib	I	>/3 mm	Asymptomatic  from MBMs	No prior resection,  SRS, or WBRT	Modified RECIST
Amaravadi	2009	Sorafenib and  temozolomide	II		Stable or clinically  asymptomatic	Prior radiation  allowed if steroids  discontinued	RECIST
Long	2012	Dabrafenib	II	5–40 mm	Asymptomatic  from MBMs	Cohort A: no prior  local therapy Cohort  B: progressive  disease after local  therapy	Modified RECIST 1.1
Dummer	2014	Vemurafenib	Pilot	Measurable disease  not required		Prior local therapy  required	RECIST 1.1
Margolin	2012	Ipilimumab	II	5–30 mm, and/or 2  measurable  lesions >3 mm		Prior irradiation  allowed, untreated  lesions required.	Modified WHO